[{"address1": "2 Burlington Woods Drive", "address2": "Suite 100", "city": "Burlington", "state": "MA", "zip": "01803", "country": "United States", "phone": "781 552 4452", "website": "https://www.bonebiologics.com", "industry": "Medical Devices", "industryKey": "medical-devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.", "fullTimeEmployees": 2, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jeffrey  Frelick", "age": 57, "title": "CEO & President", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 325000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Deina H. Walsh", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 212500, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.72, "open": 1.65, "dayLow": 1.63, "dayHigh": 1.75, "regularMarketPreviousClose": 1.72, "regularMarketOpen": 1.65, "regularMarketDayLow": 1.63, "regularMarketDayHigh": 1.75, "beta": 0.701, "forwardPE": -0.7899543, "volume": 79919, "regularMarketVolume": 79919, "averageVolume": 4227659, "averageVolume10days": 584300, "averageDailyVolume10Day": 584300, "marketCap": 3627360, "fiftyTwoWeekLow": 0.8, "fiftyTwoWeekHigh": 10.56, "fiftyDayAverage": 1.66366, "twoHundredDayAverage": 2.01033, "currency": "USD", "enterpriseValue": 784400, "floatShares": 1721804, "sharesOutstanding": 2096740, "sharesShort": 48584, "sharesShortPriorMonth": 28646, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0232, "heldPercentInsiders": 0.05211, "heldPercentInstitutions": 0.032309998, "shortRatio": 0.01, "shortPercentOfFloat": 0.0235, "impliedSharesOutstanding": 2219360, "bookValue": 2.211, "priceToBook": 0.7824514, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -5119297, "trailingEps": -17.24, "forwardEps": -2.19, "lastSplitFactor": "1:8", "lastSplitDate": 1703030400, "52WeekChange": -0.5919812, "SandP52WeekChange": 0.39389753, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BBLG", "underlyingSymbol": "BBLG", "shortName": "Bone Biologics Corp", "longName": "Bone Biologics Corporation", "firstTradeDateEpochUtc": 1634131800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef723e6d-c4c0-3645-8eff-e1206a869bb4", "messageBoardId": "finmb_99330767", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.73, "targetHighPrice": 16.75, "targetLowPrice": 16.75, "targetMeanPrice": 16.75, "targetMedianPrice": 16.75, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 2332068, "totalCashPerShare": 1.295, "quickRatio": 8.197, "currentRatio": 11.225, "returnOnAssets": -0.57252, "returnOnEquity": -1.19029, "freeCashflow": -4826930, "operatingCashflow": -6772514, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]